AGMB-447 is an inhaled small molecule lung-restricted inhibitor of ALK5 (of TGFβR1) intended for the treatment of Idiopathic Pulmonary Fibrosis (IPF). Idiopathic Pulmonary Fibrosis (IPF) is a devastating disease affecting over 300,000 patients worldwide. IPF is characterized by unregulated production of fibrotic, scar-like tissue that builds up in the scaffolding of the lungs. As a result, the fibrotic lung becomes stiff, hampers the patient’s ability to breathe and reduces the absorption of inhaled oxygen in the blood. Even though some medicinal treatments are available, without a lung transplant, the average survival following diagnosis is only 3-5 years. In IPF, TGFβ is a master regulator of key disease mechanisms and early clinical data supports this role. AGMB-447 is specifically designed to inhibit ALK5 in the respiratory tract while avoiding clinically relevant systemic exposure through rapid hydrolyzation in the bloodstream. Through AGMB-447, Agomab aims to reverse fibrosis in these patients.

AGMB-447 is currently being investigated in a Phase I Study to Assess Safety, Tolerability, PK and PD of AGMB-447 in Healthy Participants and Participants with IPF (NCT06181370)

“Our pipeline will continue to grow with the addition of both novel antibody and small molecule drug candidates that we are designing with the goal of bringing a range of truly disease-modifying treatments to patients in need.”


Philippe Wiesel, Chief Medical Officer